Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis

Journal of Gastroenterology

Volumn 51, Issue 7, 2016, Pages 741-747

  Toyoda, Hidenori ^a   Kumada, Takashi ^a   Tada, Toshifumi ^a   Takaguchi, Koichi ^b   Ishikawa, Toru ^c   Tsuji, Kunihiko ^d   Zeniya, Mikio ^e   Iio, Etsuko ^f   Tanaka, Yasuhito ^f  

^a OGAKI MUNICIPAL HOSPITAL   (Japan)

^b KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^c Saiseikai Niigata Dai Ni Hospital   (Japan)

^d TEINE KEIJINKAI HOSPITAL   (Japan)

^e INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^f NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Chronic hepatitis C; Direct acting antiviral drugs; Hemodialysis; Safety; Viral response

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ASUNAPREVIR; DACLATASVIR; HEMOGLOBIN; VIRUS RNA; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; SULFONAMIDE;

ADVERSE OUTCOME; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; CHRONIC HEPATITIS C VIRUS GENOTYPE 1 INFECTION; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ERADICATION; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG SAFETY; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; FEMALE; HEMODIALYSIS; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIVER INJURY; LIVER METABOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPENSITY SCORE; SIDE EFFECT; TREATMENT RESPONSE; VIRAL CLEARANCE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; CONTROLLED CLINICAL TRIAL; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; TREATMENT OUTCOME; VIROLOGY;

AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; ISOQUINOLINES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84957948100     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-016-1174-4     Document Type: Article

References (39)

1. Berenguer M. Treatment of chronic hepatitis C in hemodialysis patients. Hepatology. 2008;48(5):1690–9.
2. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology. 2002;36(1):3–10.
3. Martin P, Fabrizi F. Hepatitis C virus and kidney disease. J Hepatol. 2008;49(4):613–24.
4. Liu CH, Kao JH. Treatment of hepatitis C virus infection in patients with end-stage renal disease. J Gastroenterol Hepatol. 2011;26(2):228–39.
5. Stehman-Breen CO, Emerson S, Gretch D, et al. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis. 1998;32(4):629–34.
6. Pereira BJ, Natov SN, Bouthot BA, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. Kidney Int. 1998;53(5):1374–81.
7. Espinosa M, Martin-Malo A, Alvarez de Lara MA, et al. Risk of death and liver cirrhosis in anti-HCV positive long-term hemodialysis patients. Nephrol Dial Transplant. 2001;16(8):1669–74.
8. Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol. 2000;11(10):1896–902.
9. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366(3):216–24.
10. Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology. 2012;55(3):724–8.
11. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1 infection. Hepatology. 2014;59(6):2083–91.
12. Garimella T, Wang R, Luo WL, et al. Single-dose pharmacokinetics and safety of daclatasvir in subject with renal function impairment. Antivir Ther. 2015;20(5):535–43.
13. Garimella T, He B, Luo WL, et al. Asunaprevir pharmacokinetics and safety in subjects with impaired renal function. Hepatology. 2013;58(10):430A.
14. Ohno O, Mizokami M, Wu RR, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol. 1997;35(1):201–7.
15. Uchida Y, Kouyama J, Naiki K, Mochida S. A novel simple assay system to quantify the percent HCV RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors. PLoS One. 2014;9(11):e112647.
16. Lopes EPA, Gouveia EC, Albuquerque ACC, et al. Determination of the cut-off of serum alanine aminotransferase in patients undergoing hemodialysis, to identify biochemical activity in patients with hepatitis C viremia. J Clin Virol. 2006;35(3):298–302.
17. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–92.
18. Guh JY, Lai YH, Yang CY, et al. Impact of decreased serum transaminase levels on the evaluation of viral hepatitis patients. Nephron. 1995;69(4):459–65.
19. Yuki N, Ishida H, Inoue T, et al. Reappraisal of biochemical hepatitis C activity in hemodialysis patients. J Clin Gastroenterol. 2000;30(2):187–94.
20. Liu CH, Huang CF, Liu CJ, et al. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naïve patients with hepatitis C virus genotype 1 receiving hemodialysis. A randomized trial. Ann Intern Med. 2013;159(11):729–38.
21. Deltenre P, Moreno C, Tran A, et al. Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy. Alim Pharmacol Ther. 2011;34(4):454–61.
22. Toyoda H, Kumada T, Kiriyama S, et al. An early viral response to standard interferon-alpha identifies resistance to combination therapy with peginterferon and ribavirin in patients infected by HCV genotype 1. J Med Virol. 2010;82(9):1537–44.
23. Toyoda H, Kumada T, Tada T, et al. Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load. J Gastroenterol Hepatol. 2010;25(6):1072–8.
24. Fujiwra K, Kaneko S, Kakumu S, et al. Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load. Hepatol Res. 2007;37(9):701–10.
25. Kaneko S, Sata M, Ide T, et al. Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis C. Hepatol Res. 2010;40(11):1072–81.
26. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther. 2003;18(11–12):1071–81.
27. Russo MW, Goldsweig CD, Jacobson IM, Brown RS Jr. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol. 2003;98(7):1610–5.
28. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8:280–8.
29. Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999;29:1124–30.
30. Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med. 1998;129:94–9.
31. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med. 1999;131:174–81.
32. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology. 1998;27:1394–402.
33. Ogawa E, Furusyo N, Kajiwara E, et al. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: a prospective multicenter study. J Hepatol. 2013;58:495–501.
34. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–93.
35. Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206:469–77.
36. Tada T, Kumada T, Toyoda H, et al. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis. Liver Int (in press).
37. Tanaka J, Katayama K, Matsuo J, et al. The association of hepatitis C virus infection with the prognosis of chronic hemodialysis patients: a retrospective study of 3,064 patients between 1999 and 2010. J Med Virol. 2015;87:1558–64.
38. Roth D, Nelson DR, Bruchefeld A, et al. Grazoprevir plus elbasvir in treatment-naïve and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015;386(10):1537–45.
39. Pockros PJ, Reddy KR, Mantry PS, et al. Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCVGT1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-1 study. J Hepatol. 2015;62(Suppl 1):S1145A.